Evidence map›Paper›PMID 23392176›Full record

ArticleCell death & disease2013

Retinitis pigmentosa: rapid neurodegeneration is governed by slow cell death mechanisms.

A Sahaboglu, O Paquet-Durand, J Dietter, K Dengler, S Bernhard-Kurz, P Ar Ekström, B Hitzmann, M Ueffing, F Paquet-Durand

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. AnFrontiers in neuroscience · 2020
    Article
  15. Article
  16. Combination of cGMP analogue and drug delivery system provides functional protection in hereditary retinal degeneration.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

A SahabogluInstitute for Ophthalmic Research, University of Tübingen, Tübingen, Germany.
O Paquet-Durand
J Dietter
K Dengler
S Bernhard-Kurz
P Ar Ekström
B Hitzmann
M Ueffing
F Paquet-Durand
University of Tübingen · DEUniversity of Stuttgart · DELund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For most neurodegenerative diseases the precise duration of an individual cell's death is unknown, which is an obstacle when counteractive measures are being considered. To address this, we used the rd1 mouse model for retinal neurodegeneration, characterized by phosphodiesterase-6 (PDE6) dysfunction and photoreceptor death triggered by high cyclic guanosine-mono-phosphate (cGMP) levels. Using cellular data on cGMP accumulation, cell death, and survival, we created mathematical models to simulate the temporal development of the degeneration. We validated model predictions using organotypic retinal explant cultures derived from wild-type animals and exposed to the selective PDE6 inhibitor zaprinast. Together, photoreceptor data and modeling for the first time delineated three major cell death phases in a complex neuronal tissue: (1) initiation, taking up to 36 h, (2) execution, lasting another 40 h, and finally (3) clearance, lasting about 7 h. Surprisingly, photoreceptor neurodegeneration was noticeably slower than necrosis or apoptosis, suggesting a different mechanism of death for these neurons.

Indexed as

AnimalsApoptosisCells, CulturedCyclic GMPCyclic Nucleotide Phosphodiesterases, Type 6MiceModels, BiologicalMutationNeuronsPhosphodiesterase InhibitorsPhotoreceptor Cells, VertebratePurinonesRetinaRetinitis PigmentosaCyclic GMPCyclic Nucleotide Phosphodiesterases, Type 6Phosphodiesterase InhibitorsPurinoneszaprinast

Identifiers

PMID23392176
PMCPMC3593146
OpenAlexW2127358297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.